L·DOPA AND SCHIZOPHRENIA* PAUL E. GARFINKEL, M.D. 1 HARVEY C. STANCER, M.D. 2 maintenance L-thyroxine 0.2 mg, and made a good recovery in three weeks. However, she was readmitted while stuporous five months later. On this occasion she responded to a course of electroconvulsive therapy (ECT).
In May 1969 she again became stuporous and required hospitalization. Treatment with chlorpromazine and later thioridazine did not alter her psychological state. Ten ECT brought about only a slight amelioration. Intravenous sodium amytal resulted in consistent transient improvements.
After eleven months in hospital she was transferred to the Clarke Institute of Psychiatry. She appeared rigid, immobile, almost mute and with markedly flattened affect. Physical examination was normal except for mild bilateral resting tremor of her hands and an oily skin with erythematous patches. Laboratory tests, including routine hematology, urinalysis, serum proteins, serum folate and vitamin B 12 , T 4 , T 3 resin uptake, urinary 17-Keto and hydroxysteriods and porphyrines, were normal, Urinary homovanillic acid (HVA) was 1.7 and 2.6 mg per 24 hours (Normal < IS). HVA was not detectable in cerebrospinal fluid.
Initially this patient was treated with haloperidol but when her condition seemed to worsen she was given triiodothyronine 25 JLg q.i.d. as a modification of Gjessing's treatment (3), without improvement. A course of 14 ECT resulted in minimal change. While in hospital she developed rheumatoid arthritis which was managed symptomatically with acetylsalicyclic acid, but there was no change in her mental state associated with the arthritis.
Six months after transfer to the Clarke Institute she was started on L-Dopa. At this time she was almost mute, answering questions with one or two words, and her affect was flat.
CANADIAN PSYCHIATRIC ASSOCIATION JOURNAL Vol. 21, No. I Although she had no hallucinations she was deluded, believing that the world was coming to an end. When the dose of L-Dopa was increased to 4 g per day some improvement in her mental state was noted. Improvement progressed as L-Dopa was increased to 7 g per day. At that time her conversation was spontaneous, her affect was appropriate and she was no longer delusional. She was physically active in ward activities and her skin appeared normal. Despite this dramatic change it was not felt that she had improved sufficiently to manage on her own outside hospital. At 8 g of L-Dopa she developed a toxic confusional state which responded to a reduction of L-Dopa to 7 g per day. Three months after beginning L-Dopa, placebo was substituted to assess her drug-free condition, and within one week she was noted to be deteriorating. Two weeks after commencing placebo her condition was similar to that on admission.
L-Dopa was restarted and gradually increased until the patient was receiving 7.5 g per day.
There was no improvement in her condition in spite of maintaining this dose for four weeks. The L-Dopa was discontinued temporarily and L-alphamethyl-alphahydrazino-3, 4-dihydroxphenyl propionicacid (MK-486), a peripheral decarboxylase inhibitor, was initiated at 100 mg per day. L-Dopa was then slowly increased to 2.5 g per day while the patient remained on MK-486. No improvement in her mental condition resulted in spite of the combined therapy.
Discussion
This patient had a history of both catatonic excitement and stupor. Prior to beginning the L-Dopa she had been hospitalized in a withdrawn state for a period of seventeen months. She showed dramatic sustained improvement on 7 g L-Dopa per day. Her state deteriorated with placebo substitution. However, she did not improve a second time in spite of high doses of L-Dopa, even after combining this drug with a decarboxylase inhibitor.
Why this patient showed a dramatic response to L-Dopa on one occasion, but failed to respond a second time is a matter of speculation. It is possible that the first response was a spontaneous remission which coincided with the use of L-Dopa. But this seems unlikely in view of her steadily regressed state for seventeen months prior to improvement and also her subsequent unchanged condition over the last two years. Another possibility for the lack of clinical response on the second occasion is that the L-Dopa was not entering the central nervous system in sufficient quantities to raise brain dopamine. This was the reason for the concurrent use of the peripheral decarboxylase inhibitor as this has been demonstrated to increase the L-Dopa accumulation in brain (2) . It would appear that an adequate dose ofMK-486 was used, in view of Jaffe's (5) finding of 75 mg being as effective as higher doses in allowing a maximal (70 percent) reduction in L-Dopa dosage for parkinsonian patients. However, in the case of this patient no benefit resulted from the drug combination.
The use of L-Dopa has been reported in the treatment of depressed patients, generally with poor results (6, 7) . Goodwin et al. , (4) have described a differential response to L-Dopa, depending on whether the clinical picture is primarily one of agitation or retardation. While only six of twenty-one depressed patients consistently improved on L-Dopa with relapse following placebo substitution and remission on restoration of the drug, the responders were all retarded depressives. Similarly, while the schizoprenic patients of Angrist et al. deteriorated on L-Dopa, agitation and hyperactivity were prominent. Part of this patient's response was manifested by her greater spontaneity and increased motor activity. It is possible that all these patients treated with L-Dopa experienced nonspecific activation due to an increase in brain dopamine, and this may have been responsible for our patient's manifest behavioural change.
' Contrary to reports in the literature this patient did not show a worsening of her symptomatology from the L-Dopa and she, at least transiently, improved while on it.
Summary
Previous reports have emphasized the deterioration of schizophrenic patients when given L-Dopa. The authors described a patient with long-standing catatonic schizophrenia who was not helped by conventional therapies but initially responded dramatically to L-Dopa. Placebo substitution resulted in worsening of her condition but restarting the L-Dopa did not bring about any change, in spite of combining this with a peripheral decarboxylase inhibitor. The authors postulate that the effects seen in this patient may be related to the general activating effect of increased brain dopamine.
